Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab?
作者信息
Breillat Paul, Mathian Alexis, Rozenberg Flore, Dutheil Amélie, Barbaud Annick, Amoura Zahir, Chasset François
机构信息
Centre de Référence pour le Lupus, le Syndrome Des Anti-Phospholipides et Autres Maladies Auto-Immunes Rares, Service de Médecine Interne 2, Institut E3M, Hôpitaux de Paris (AP-HP), 26933Groupement Hospitalier Pitié-Salpêtrière, Paris, France.
27063Sorbonne Université, Paris, France.
出版信息
Lupus. 2023 Mar;32(3):453-455. doi: 10.1177/09612033231153536. Epub 2023 Jan 19.
Abstract
摘要
相似文献
1
Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab?接受阿尼氟单抗治疗的系统性红斑狼疮患者发生重症新型冠状病毒肺炎的风险是否增加？
Lupus. 2023 Mar;32(3):453-455. doi: 10.1177/09612033231153536. Epub 2023 Jan 19.
2
Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: analysis of the Phase IIb MUSE trial of anifrolumab.狼疮低疾病活动状态（LLDAS）达标可区分系统性红斑狼疮试验中的应答者：阿尼鲁单抗的 IIb 期 MUSE 试验分析。
Ann Rheum Dis. 2018 May;77(5):706-713. doi: 10.1136/annrheumdis-2017-212504. Epub 2018 Feb 2.
3
Treatment With Anifrolumab for Discoid Lupus Erythematosus.阿尼鲁单抗治疗盘状红斑狼疮
JAMA Dermatol. 2023 Feb 1;159(2):224-226. doi: 10.1001/jamadermatol.2022.5242.
4
Anifrolumab in Systemic Lupus Erythematosus.阿尼鲁单抗治疗系统性红斑狼疮
N Engl J Med. 2020 Apr 23;382(17):1665-1666. doi: 10.1056/NEJMc2002191.
5
Anifrolumab in Systemic Lupus Erythematosus. Reply.阿尼鲁单抗治疗系统性红斑狼疮。回复。
N Engl J Med. 2020 Apr 23;382(17):1666. doi: 10.1056/NEJMc2002191.
6
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.阿尼鲁单抗治疗活动性系统性红斑狼疮的试验。
N Engl J Med. 2020 Jan 16;382(3):211-221. doi: 10.1056/NEJMoa1912196. Epub 2019 Dec 18.
7
Anifrolumab in systemic lupus erythematosus.阿尼鲁单抗治疗系统性红斑狼疮。
Drugs Today (Barc). 2023 Feb;59(2):53-61. doi: 10.1358/dot.2023.59.2.3521876.
8
Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.一种针对 I 型干扰素受体的单克隆抗体 anifrolumab 在日本系统性红斑狼疮患者中的安全性和耐受性：一项多中心、开放标签、2 期研究。
Mod Rheumatol. 2020 Jan;30(1):101-108. doi: 10.1080/14397595.2019.1583833. Epub 2019 Mar 21.
9
The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis.在日本系统性红斑狼疮患者中阿尼鲁单抗的疗效和安全性：TULIP-2 子分析。
Mod Rheumatol. 2023 Jan 3;33(1):134-144. doi: 10.1093/mr/roac010.
10
Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.阿尼鲁单抗，一种针对 I 型干扰素受体亚单位 1 的单克隆抗体，用于治疗系统性红斑狼疮：临床试验概述。
Mod Rheumatol. 2021 Jan;31(1):1-12. doi: 10.1080/14397595.2020.1812201. Epub 2020 Sep 17.
引用本文的文献
1
Anifrolumab: the new frontier in the treatment of genetic interferonopathies.阿尼鲁单抗：遗传性干扰素病治疗的新前沿。
RMD Open. 2024 Sep 23;10(3):e004780. doi: 10.1136/rmdopen-2024-004780.
2
Dangers of Herpesvirus Infection in SLE Patients Under Anifrolumab Treatment: Case Reports and Clinical Implications.阿尼鲁单抗治疗系统性红斑狼疮患者中疱疹病毒感染的危险：病例报告及临床意义。
Am J Case Rep. 2024 Sep 9;25:e944505. doi: 10.12659/AJCR.944505.
Zotero 插件